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Abstract
Several recent studies have documented that supplementation with pomegranate fruit extract
inhibits inflammatory symptoms in vivo. However, the molecular basis of the observed effects has
not been fully revealed. Although previous studies have documented the inhibition of nitric oxide
and cyclooxygenase (COX) activity in vitro by plant and fruit extracts added directly into the culture
medium but whether concentrations of bioactive compounds sufficient enough to exert such
inhibitory effects in vivo can be achieved through oral consumption has not been reported. In the
present study we determined the effect of rabbit plasma obtained after ingestion of a polyphenol
rich extract of pomegranate fruit (PFE) on COX enzyme activity ex vivo and the IL-1β-induced
production of NO and PGE2 in chondrocytes in vitro. Plasma samples collected before and 2 hr after
supplementation with PFE were tested. Plasma samples collected after oral ingestion of PFE were
found to inhibit the IL-1β-induced PGE2 and NO production in chondrocytes. These same plasma
samples also inhibited both COX-1 and COX-2 enzyme activity ex vivo but the effect was more
pronounced on the enzyme activity of COX-2 enzyme. Taken together these results provide
additional evidence of the bioavailability and bioactivity of compounds present in pomegranate fruit
after oral ingestion. Furthermore, these studies suggest that PFE-derived bioavailable compounds
may exert an anti-inflammatory effect by inhibiting the inflammatory cytokine-induced production
of PGE2 and NO in vivo.
Background
Pomegranate has been used for centuries to confer health
benefits in a number of inflammatory diseases. Based on
its usage in Ayurvedic and Unani medicine, dietary sup-
plements containing pomegranate extract are becoming
popular in the Western world for the treatment and pre-
vention of arthritis and other inflammatory diseases.
More recently standardized extracts of pomegranate fruit
(PFE) have been shown to possess anti-inflammatory and
cartilage sparing effects in vitro [1]. Published studies have
shown that constituents of PFE inhibit the proliferation of
human cancer cells and also modulate inflammatory sub-
Published: 13 June 2008
Journal of Inflammation 2008, 5:9 doi:10.1186/1476-9255-5-9
Received: 25 October 2007
Accepted: 13 June 2008
This article is available from: http://www.journal-inflammation.com/content/5/1/9
© 2008 Shukla et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
Page 2 of 10
(page number not for citation purposes)
cellular signaling pathways and apoptosis when directly
added to the culture medium [2-6]. PFE has also been
shown to significantly reduce the growth of prostate
tumors and the levels of prostate-specific antigen (PSA) in
nude mice implanted with prostate cancer cells [7]. Sev-
eral groups have reported that consumption of pomegran-
ate may have cholesterol lowering and cardiovascular and
other chronic diseases preventing effects in vivo [8-11]. In
these studies the major effect of the pomegranate extract
consumption was the reduction of oxidative stress, inhibi-
tion of p38-mitogen-activated protein kinase (p38-
MAPK) pathway and inhibition of the activation of tran-
scription factor NF-κB. Activation of p38-MAPK and NF-
κB is intimately associated with the increased gene expres-
sion of TNF-α, IL-1β, MCP1, iNOS and COX-2-agents that
are critical mediators of inflammation and the pathogen-
esis of inflammatory and degenerative joint diseases
[12,13]. These and other published studies [[14],
reviewed in [15,16]] thus demonstrate that PFE possesses
strong antioxidant and anti-inflammatory properties and
its consumption has the potential to prevent diseases in
which redox imbalance and inflammatory stimuli plays a
decisive role.
The major class of phytochemical present in pomegranate
is the polyphenols and includes flavonoids, condensed
tannins and hydrolysable tannins. Hydrolysable tannins
are predominant polyphenols found in pomegranate
juice and account for 92% of its antioxidant activity [14].
Pomegranate seeds are rich in sugars, polyunsaturated (n-
3) fatty acids, vitamins, polysaccharides, polyphenols,
and minerals and have high antioxidant activity. When
crushed and dried, the seeds produce an oil with 80%
punicic acid, the 18-carbon fatty acid, along with the iso-
flavone genistein, the phytoestrogen coumestrol, and the
sex steroid estrone. The seed coat of the fruit contains del-
phinidin-3-glucoside, delphinidin-3,5-diglucoside, cyani-
din-3-glucoside, cyanidin-3,5-diglucoside, pelargonidin-
3-glucoside, and pelargonidin-3,5-diglucoside with del-
phinidin-3,5-diglucoside being the major anthocyanin in
pomegranate juice [11]. Studies have also shown that the
antioxidant capacity of pomegranate juice is three times
that of the popular antioxidant-containing beverages such
as red wine and green tea, presumably due to the presence
of hydrolyzable tannins in the rind, along with anthocy-
anins and ellagic acid derivatives [14]. In a comparative
analysis, anthocyanins from pomegranate fruit were also
shown to possess higher antioxidant activity than vita-
min-E (α-tocopherol), ascorbic acid and β-carotene [17].
Pomegranate extract has also been shown to protect from
NSAID and ethanol-induced gastric ulceration [18].
Repeated administration of high doses of a hydroalco-
holic extract of pomegranate whole fruit or its constituent
ellagitannin punicalagin were non toxic in the dosages
commonly employed in traditional medicine systems
[19,20].
Flavonoid rich fractions of pomegranate fruit extract have
also been shown to exert antiperoxidative effect as their
administration significantly decreased the concentrations
of malondialdehyde, hydroperoxides and enhanced the
activities of catalase, superoxide dismutase, glutathione
peroxidase and glutathione reductase in the liver [21,22].
Anthocyanins were shown to be effective inhibitors of
lipid peroxidation, the production of nitric oxide (NO)
and inducible nitric oxide synthase (iNOS) activity in dif-
ferent model systems [22-24]. After consumption,
anthocyanins are efficiently absorbed as glycosides from
the stomach and are rapidly excreted into bile as intact
and metabolized forms [25,26]. Plasma concentration of
30 μg/ml of punicalagin and 213 ng/ml of ellagic acid
after oral administration in rats has been reported [27]. In
humans it has been shown that ellagic acid is rapidly
absorbed and plasma concentrations of 31.9 ng/ml were
detected within one hour of oral consumption of pome-
granate juice [28]. Cyclooxygenase (COX), an enzyme
involved in the mediation of inflammatory process, cata-
lyzes the rate-limiting step in the synthesis of prostaglan-
dins from arachidonic acid [29,30]. Of its two isoforms,
COX-1 is constitutively expressed in most tissues and
appears to be responsible for maintaining normal physio-
logical functions whereas COX-2 has been shown to be
involved in cutaneous inflammation, cell proliferation,
and skin tumor promotion [31]. These data suggest that
inhibition of COX-2 activity is important for alleviating
inflammation. Other studies have shown that Prodelphi-
nidins isolated from Ribes nigrum inhibit cyclooxygenase-
2 (COX-2) and lipoxygenase activity and production of
prostaglandins E2 (PGE2) in vitro, suggesting that the pri-
mary effect of delphinidins (also present in pomegranate
fruit) may be against inflammatory responses [32]. More
recently it has been shown that pomegranate extract
exerted a powerful influence in inhibiting the expression
of inflammatory cytokines IL-1β and IL-6 in adjunctive
periodontal therapy [33]. Other in vitro studies have
shown that the bioactivity of total pomegranate extract
was superior to its purified individual polyphenols illus-
trating the multifactorial effects and chemical synergy of
the action of multiple compounds present therein [2].
While evidence from in vitro studies does not prove in vivo
biological activity, these do provide a rationale and sup-
port for the use of pomegranate fruit or its extract to sup-
press inflammation in vivo. However, it is also important
to point out that there are issues that deserve an explana-
tion and require caution in interpreting the data obtained
from in vitro studies. One question often raised is whether
the concentration of a plant or fruit extract constituent
compound that has been used in in vitro experimentsJournal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
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would be realistic or achievable in vivo. In majority of the
cases this has to be denied because constituents of plant
or fruit extracts are typically not completely bioavailable
and only certain constituents can be expected to be
absorbed and become bioavailable via the hepatic portal
system [34]. Another issue to be considered is that the bio-
effective compounds do not necessarily need to be present
in the original extract, but might be formed in vivo due to
intestinal bacterial and/or hepatic metabolism [34]. This
is supported by recent studies demonstrating that after
ingestion of pomegranate juice by human volunteers
ellagic acid metabolites which were not present in the
juice consumed such as dimethylellagic acid glucuronide
were detected in plasma and urine while Urolithins-
formed by intestinal bacteria-were detected in the urine
samples [35].
Pomegranate fruits are popularly consumed throughout
the world and fruit and flower extracts are widely used for
the treatment of inflammatory diseases in the traditional
medicine systems of Asia and Europe. In this study using
rabbits we determined whether after oral ingestion of a
standardized preparation of pomegranate fruit extract
(PFE), blood plasma samples contained PFE-derived
metabolites/constituents by HPLC-DAD analysis. To test
whether these same plasma samples exert anti-inflamma-
tory effects, we determined whether the presence of these
plasma samples in the assay mixture or culture medium
can (a) inhibit the enzymatic activity of purified cycloox-
ygenases ex vivo; and (b) inhibit IL-1β-induced produc-
tion of nitric oxide (NO) and PGE2 by rabbit articular
cartilage chondrocytes in vitro.
Methods
Preparation of pomegranate fruit extract (PFE)
Pomegranate fruit (POMWonderful) was procured from
the market and the extract was prepared essentially as pre-
viously described [1]. The filtrate was condensed and
freeze-dried and stored at -20°C prior to use. For use
required concentration of the freeze dried preparation was
dissolved in sterile water.
Total phenolics
The total phenolics were determined by the Folin-Ciocal-
teau method as previously described [36]. Briefly, 50 mg
of the dried powder was extracted with 100 ml of acidified
methanol:water (60:40 v/v, 0.3% HCl) and filtered. Fil-
trate was mixed with equal amounts of the Folin-Ciocal-
teau reagent (Sigma) and 2.0 ml of sodium bicarbonate
was added and mixed thoroughly. After 2 h, absorbance
was measured at 725 nm and the values were derived from
a standard curve prepared using Tannic acid (0 – 1.0 mg/
ml in acidified methanol:water). Values were expressed as
mg/gm Tannic acid equivalents (mg/gm of TAE).
Rabbits
For these studies we used 6 New Zealand white rabbits
(male, 1 yr old, Average weight 3.7 Kg). Rabbits were accli-
matized for one week and were then divided into 2
groups: (1) Experimental (4 rabbits); and (2) Control (2
rabbits). Rabbits in both the groups were food starved
overnight and the next morning experimental rabbits
were given 10 ml of PFE (34 mg/Kg) by gavage. Based on
the phenolics content of PFE this dose was equivalent to
175 ml of pomegranate juice. The control rabbits were
given just 10 ml of water the same way. Blood (10 ml) was
collected prior to supplementation with PFE (Control
plasma) and at 2 h post supplementation with PFE
(Experimental plasma) in EDTA tubes (Becton Dickin-
son) and plasma was separated by standard methods and
stored at -80°C prior to use.
Extraction of anthocyanins from blood and HPLC analysis
The EDTA blood samples were centrifuged at 500 g for 10
min at 4°C, and the plasma was quickly removed. A 0.5
mL aliquot of plasma was acidified with acetic acid (10
mM) to prevent degradation of polyphenols related
metabolites and was stored at -70°C until the analyses.
For analysis by HPLC, 1 ml of acidified plasma was mixed
with MeOH:0.2 M HCl (1:1, v:v), vortexed for one min
and centrifuged at 14,000 g for 2 min at 4°C. The super-
natant was filtered through a 0.45 μm filter and 10 μl of
the filtrate was directly analyzed by HPLC-DAD using Agi-
lent 1100 system on a reversed-phase C 18 column
(Eclipse XDB 150 × 4.6 mm; particle size 5 μM). Solvent
(A) was 0.1% (v/v) TFA/Water and solvent (B) was 0.1%
TFA/Acetonitrile and a flow rate of 1 ml/min was main-
tained (initial 3% B, then 0–2 min 3% B; 2–32 min 3% –
60% B; 32 – 37 min 60% B; 37 – 38 min 60% to 3% B).
Ellagic acid standard (Chromadex) was dissolved in
DMSO and was found to elute at 24.6 min using the
above described parameters.
Preparation of chondrocytes and treatment
Rabbit chondrocytes were prepared from the articular car-
tilage by enzymatic digestion as previously described for
human chondrocytes [1,37]. Chondrocytes were plated (1
× 106/ml) in 48 well culture plates (Becton-Dickinson,
Franklin Lakes, NJ) in complete DMEM with 10% foetal
calf serum and allowed to grow for 72 h at 37°C and 5%
CO2 in a tissue culture incubator. Chondrocytes (>80%
confluent) were serum-starved overnight and then pre-
treated with either control or experimental rabbit blood
plasma for 2 hrs and then stimulated with IL-1β (5 ng/ml)
for 24 hrs. Chondrocytes cultured without IL-1β served as
controls in all of the experiments. Cell viability before
plating was monitored by the MTT assay (Cell Viability
and Proliferation Assay) according to the instructions of
the manufacturer (R&D Systems). In some cases, viabilityJournal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
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of chondrocytes after exposure to PFE and IL-1β was deter-
mined by Trypan blue exclusion assay.
Determination of COX activity by EIA
The COX-1 and COX-2 inhibitory assay was carried out
using a COX Inhibitor Screening Assay Kit (Cayman
Chemicals, Ann Arbor, MI) according to the instructions
provided with the kit. Briefly, heme and COX enzymes
were added to the tubes containing the kit supplied reac-
tion buffer and the mixture was vortexed and mixed with
either reaction buffer or an aliquot (20 μl) of plasma sam-
ple diluted 5 fold in the same buffer and incubated at
37°C for 10 min. Acetylsalicylic acid was used as positive
control. Arachidonic acid solution was then added to the
tubes to start the cyclooxygenase reaction and after incu-
bation at 37°C for 2 min, 1M HCl was added to terminate
the reaction. PGH2 formed was reduced to PGF2α with sat-
urated stannous chloride solution. The COX activity was
measured based on the amount of PGF2α detected by the
enzyme immunoassay kit using a standard curve. The
COX enzyme inhibitory activity of plasma samples
obtained before the oral ingestion of PFE (Control) was
compared to COX enzyme activity inhibition induced by
plasma samples obtained 2 h after the oral ingestion of
PFE (Experimental). For each measurement, control and
experimental plasma samples obtained from the same
rabbit were used. Values obtained were expressed a per-
cent COX enzyme activity remaining relative to activity of
the control enzyme (kit supplied) which was taken as
100% activity when the assay was performed in the
absence of inhibitors.
Determination of nitric oxide
The nitrite concentration in the chondrocytes culture
medium was measured by the Griess reaction as an indi-
cator of NO production. Briefly, 100 μl of culture super-
natant was mixed with 900 μl of Griess reagent (1%
sulphanilamide in 5% phosphoric acid and 0.1% naphth-
ylethylenediamine dihydrochloride in water) and incu-
bated for 15 min at room temperature. Absorbance of the
mixture at 540 nm was determined using λ 25 Spectro-
photometer (Perkin-Elmers, CT) and the concentration
was derived using a standard curve prepared with sodium
nitrite.
Measurement of PGE2 production
Levels of PGE2 in the chondrocytes culture supernatant
were quantified using a commercially available kit (R & D
Systems, Cat# KGE004) according to the instructions pro-
vided with the kit.
Statistical analysis
Experiments were repeated and each assay was performed
in triplicate. Data was analyzed using the InStat 3.0
(GraphPad) software package (unpaired two tailed t-test
with Welch correction) and P < 0.05 was considered sig-
nificant. Values shown are Mean ± SE of Mean unless
stated otherwise.
Results
PFE-derived metabolites in the blood
The known antioxidant and antiatherosclerotic properties
of pomegranate are mainly attributed to the high content
of polyphenols, including hydrolysable tannins and ellag-
itannins (ET), present in the pomegranate fruit [14]. The
extract was found to contain 107.5 ± 3 mg/g total
polyphenolics expressed as tannic acid equivalents (TAE,
mg/g of TAE). The HPLC chromatogram of the PFE used
in this study showed the presence of several polyphenols
including ellagic acid (EA) (at tR 24.6 min, results not
shown). For the HPLC analyses ellagic acid was used as a
marker since EA has been shown to become bioavailable
after oral consumption of pomegranate juice and the pres-
ence of EA in blood and urine has been suggested as a reli-
able marker for assessing compliance in studies involving
the consumption of pomegranate fruit [35]. Control
plasma samples showed no peak corresponding to EA on
HPLC chromatogram (Figure 1A) while a peak corre-
sponding to EA was detected in the plasma samples
obtained 2 h after the ingestion of PFE from the same ani-
mal (Figure 1C and results not shown). Additional peaks
detected in the experimental plasma samples at tR 27.9, tR
34.1, tR 34.7 and tR 36.8 (Figure 1C &1D) were also not
detected in the control blood samples (Figure 1A &1B)
and therefore are likely to be PFE-derived. These results
confirm the previous findings [26-28,35] and demon-
strate that PFE constituents and PFE-derived metabolites
become bioavailable after oral ingestion.
Inhibition of COX activity
After ingestion of a concentrated dose of PFE, the incuba-
tion of plasma samples with purified COX-1 and COX-2
enzymes showed a direct inhibitory effect on the enzyme
activity (Figure 2). In the assay procedure, plasma was
diluted 10 fold before the COX reaction was started. Incu-
bation with plasma samples obtained before the oral
ingestion of PFE suppressed the COX-1 activity by 14.85 ±
2.41% while incubation with blood samples obtained
after supplementation with PFE suppressed the COX-1
activity by 21.47 ± 3.64%. This inhibition of COX-1
enzyme activity when post-supplementation plasma was
added directly in the assay system was statistically signifi-
cant when compared to the activity level in controls (P <
0.05). In contrast, incubation of COX-2 enzyme with pre-
supplementation plasma inhibited the enzyme activity by
12.27 ± 4.79% (P > 0.05 compared to control) but incu-
bation with post supplementation plasma inhibited the
COX-2 activity by 38.8 ± 9.59% and this inhibition of
COX 2 enzyme activity was statistically highly significant
(P < 0.05). The mean PGF2α concentrations detected afterJournal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
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incubation of COX-1 enzyme with arachidonic acid in the
presence of pre-supplementation plasma samples were
254.33 ± 4.5 ng/ml and 247.66 ± 14.97 ng/ml after incu-
bation of the enzyme with its substrate in the presence of
post-supplementation plasma. When COX-2 enzyme was
incubated with pre-supplementation plasma, the mean
PGF2α concentration detected was 592.00 ± 91.00 ng/ml.
In sharp contrast concentrations of the PGF2α were dra-
matically reduced to 199.33 ± 32.39 ng/ml when COX-2
enzyme and its substrate were incubated with the post-
supplementation plasma samples. These data clearly indi-
cate that the enzyme activity of COX-2 was significantly
influenced by PFE constituents or metabolites that
become bioavailable in the plasma after oral ingestion.
The COX-2/COX-1 ratio of inhibitory activity of the differ-
ent plasma samples was determined as previously
Pomegranate constituents and metabolites are present in blood plasma after oral ingestion of an anthocyanin and hydrolysable  tannin rich extract Figure 1
Pomegranate constituents and metabolites are present in blood plasma after oral ingestion of an anthocyanin 
and hydrolysable tannin rich extract. Representative HPLC chromatograms of plasma samples collected from rabbits 
before (A) and 2 h after consumption of PFE (B). Peak with double asterisk in B has the elution profile identical to that of puri-
fied ellagic acid standard shown in C. Peaks with single asterisk in C were detected only in plasma samples obtained after the 
oral ingestion of PFE but not in control plasma samples (blood drawn before feeding PFE).Journal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
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described [38] and was less than 1 for all of the samples
with the mean ratio being 0.80 ± 0.071 indicating selec-
tive inhibition of COX-2.
Inhibition of IL-1β-induced PGE2 production in 
chondrocytes
As our studies showed that plasma containing bioavaila-
ble PFE constituents and PFE-derived metabolites was a
potent inhibitor of COX activity ex vivo, we determined its
effect on IL-1β-induced production of PGE2 in articular
cartilage chondrocytes in vitro. Levels of PGE2 in the cul-
ture medium were estimated using an ELISA based assay.
As shown in Figure 3, control chondrocytes and chondro-
cytes treated with either plasma samples alone produced
only low levels of PGE2. Stimulation of chondrocytes with
IL-1β produced a dramatic rise in the level of PGE2 in the
culture medium indicating enhanced eicosanoid generat-
ing enzyme activity in chondrocytes. Interestingly,
chondrocytes stimulated with IL-1β in the presence of
control plasma showed no inhibition of PGE2 production
while significantly low levels of PGE2 were detected in
chondrocyte cultures stimulated with IL-1β in the pres-
ence of experimental plasma samples (Figure 3, P  <
0.005).
Inhibition of IL-1β-induced NO production in 
chondrocytes
Previous studies have shown that pomegranate extract
was an effective inhibitor of NO in different systems
[10,39,40]. However, whether blood plasma containing
bioavailable pomegranate-derived metabolites also sup-
press cytokine-induced NO production was not investi-
gated in these or other published studies. In the present
study, effect of bioavailable pomegranate-derived metab-
olites on IL-1β-induced NO production in rabbit
chondrocytes was investigated. Accumulation of nitrite in
the culture medium was determined by the Griess reac-
tion and was used as an index for NO synthesis by
chondrocytes. As shown in Figure 4, unstimulated rabbit
chondrocytes produced background levels of NO in the
culture medium. When chondrocytes were stimulated
with IL-1β, nitrite concentration in the medium increased
significantly, about 2.5 fold, (P < 0.05). When chondro-
cytes were pre-treated with pre-supplementation plasma
and then stimulated with IL-1β for 24 h, the production
of NO was reduced approximately by 25% (5.14 μM). In
contrast, a dramatic and highly significant reduction in
Effect of Plasma samples obtained before and 2 h after oral  ingestion of PFE on IL-1β-induced NO production in rabbit  chondrocytes Figure 3
Effect of Plasma samples obtained before and 2 h 
after oral ingestion of PFE on IL-1β-induced NO pro-
duction in rabbit chondrocytes. Confluent chondrocytes 
were serum starved and then treated with 200 μl of control 
or experimental plasma samples for 1 hr, stimulated with 
human IL-1β for 24 hrs. At the end of incubation, 100 μl of 
the medium was removed for measuring nitrite production 
by Griess reaction. Control values were obtained in the 
absence of plasma or IL-1β. Data were derived from two 
independent experiments, each run in triplicate, and 
expressed as Mean ± SE. Values without a common letter dif-
fer (P < 0.05 a vs b; P < 0.005, a vs c; b vs c).
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Suppression of COX 1 and COX 2 enzyme activity by plasma  of rabbits 2 h after oral administration of PFE Figure 2
Suppression of COX 1 and COX 2 enzyme activity by 
plasma of rabbits 2 h after oral administration of 
PFE. Enzyme activity of COX 2 but not of COX 1 was inhib-
ited significantly (P < 0.05) compared to control by plasma 
samples obtained 2 h after the oral ingestion of PFE (PFE-
treated plasma). Suppression of COX 1 and COX 2 enzyme 
activity by control plasma samples did not reach statistical 
significance compared to purified enzymes provided in the kit 
(P > 0.05). Acetylsalicylic acid was used as positive control 
for inhibition of COX 1 and COX 2 enzyme activity and 
showed 100% inhibition at the concentrations used. Data 
shown is Mean ± SE derived from 4 experimental and 2 con-
trol plasma samples, each run in duplicate and differ without 
a common letter (P < 0.05)Journal of Inflammation 2008, 5:9 http://www.journal-inflammation.com/content/5/1/9
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nitrite accumulation was noticed in culture medium when
chondrocytes were pre-treated with plasma obtained 2 h
after the oral ingestion of PFE and then stimulated with
IL-1β for 24 h (0.90 μM, P < 0.005). When cell viability
was checked using the Trypan Blue exclusion assay, results
indicated that incubation of chondrocytes with pre- or
post-supplementation plasma did not decrease the viabil-
ity of chondrocytes (results not shown). This indicated
that the inhibition of IL-1β-induced NO and PGE2 pro-
duction reported in this study was not a cytotoxic effect of
pomegranate-derived metabolites present in the plasma.
Discussion
The health promoting effects of plant constituents and
extracts are being increasingly studied and their consump-
tion is on the rise in the western world [41-43]. Although
several studies have reported the effectiveness of different
herbal preparations or fruit extracts for the treatment and/
or prevention of chronic diseases [reviewed in [43]], bio-
availability of the active principle(s), which could also be
metabolically derived, must be evaluated in order to pro-
vide a valid explanation for the observed or reported bio-
efficacy. This is more so as the plant or fruit extracts are a
complex mixture of various constituents and in most of
the instances it is not clear whether a single compound or
a mixture of compounds is responsible for the observed or
reported effect [34]. However, evidence is accumulating
that often related compounds present in a herb or fruit
extract augment each other's biological effect. For exam-
ple, it has been reported that ellagic acid and quercetin
(both are also present in pomegranate) together exert a
more pronounced inhibitory effect against cancer cell
growth than either compound alone [2].
Arthritis (Osteoarthritis and rheumatoid arthritis) is one
of the most prevalent and disabling chronic diseases of
the diarthrodial joints and mostly affect the elderly. Cure
for arthritis is still elusive and the management of the dis-
ease is largely palliative focusing on the alleviation of
symptoms. Current recommendations for the manage-
ment of arthritis include a combination of non-pharma-
cological interventions (weight loss, education programs,
exercise, etc) and pharmacological treatments (paraceta-
mol, nonsteroidal antiinflammatory drugs-NSAIDs, bio-
logics, etc). Among these pharmacological treatments,
NSAIDs, despite serious adverse effects associated with
their long-term use, remain among the most widely pre-
scribed drugs for relieving the pain of arthritis [44]. This
highlights a need for safe and effective alternative treat-
ments while the absence of any cure reinforces the impor-
tance of prevention. The prevention and alternative
treatments could come from nutrition. It is now becom-
ing increasingly clear that, beyond meeting basic nutri-
tional needs, consumption of certain foods may play a
beneficial role in the prevention of some chronic diseases
[45]. Arthritis being a chronic disease is the perfect para-
digm of a pathology whose prevention and/or treatment
could potentially be addressed by nutrition. This is
because, in most cases, a biologically active dietary con-
stituent has only limited effects on its target and relevant
and significant differences are only reached over time
through a cumulative effect where daily benefits add up
day after day [46]. However, bioavailability of plant, fruit
or herb constituents or metabolites after consumption
and their bioactivity must be studied before making a rec-
ommendation. In the present study we used an experi-
mental approach in which absorption and metabolism of
constituents of the popular and exotic fruit pomegranate
were taken into consideration with a view to gain an
insight into the basis of the reported in vivo anti-inflam-
matory and chemopreventive effects of its consumption
on human health [reviewed in [15,16]]. Our data show
that PFE constituents, with EA being one of them, become
bioavailable 2 h after oral ingestion of a modest amount
of concentrated pomegranate extract and that a value of
247 ng EA/ml of plasma was detected. This is very similar
to the values detected in rats [27] but in humans levels of
EA detected in the plasma after consumption of pome-
granate juice concentrate were low [28], at least at the time
points analyzed. This difference may be due to the differ-
ences in the metabolism or clearance rate between
Plasma samples obtained 2 h after oral ingestion of PFE inhib- ited IL-1β-induced PGE2 production by chondrocytes Figure 4
Plasma samples obtained 2 h after oral ingestion of 
PFE inhibited IL-1β-induced PGE2 production by 
chondrocytes. Confluent chondrocytes were serum 
starved and then treated as described for Figure 3 above. 
The amount of PGE2 produced in the medium was measured 
as described in Materials and Methods. Data were derived 
from two independent experiments, each run in duplicate. 
Values shown are Mean ± SE and differ without a common 
letter (P < 0.005).
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humans and rabbits. Additionally, EA is poorly soluble in
water and is reported to accumulate in the human intesti-
nal epithelial cells [47]. These factors could also contrib-
ute to its lower levels reported in human plasma. We also
show here for the first time that after oral ingestion of PFE,
constituents of PFE or their metabolites that become bio-
available in plasma significantly inhibited the activity of
COX-1 and COX-2 enzymes in a direct enzyme inhibition
assay with the inhibitory effect being targeted more
towards COX-2. These results suggest that these constitu-
ents of PFE or compounds derived from them may prove
to be more potent but non-toxic or less toxic inhibitors of
COX-2. Further research is needed before reaching a con-
clusion in this regard. We also show that bioavailable con-
stituents or metabolites of PFE present in the plasma were
biologically active against inflammatory mediators as
they also inhibited the inflammatory stimuli-induced
production of NO and PGE2  in chondrocytes. These
results are therefore relevant for strategies designed to pre-
vent cartilage degradation in arthritic joints and support
further studies in animal models.
There are large numbers of phytochemicals consumed in
our diet and among them polyphenols constitute the larg-
est group. Although direct inhibitory effect of plant
extracts or components on COX enzyme activity have
been reported by several investigators [47-55] but inhibi-
tion of COX enzyme activity by polyphenols that become
bioavailable after consumption of pomegranate fruit or
extract has not been reported. As we focus on the preven-
tion and treatment of arthritis by natural products, in a
previous report we showed that pomegranate extract was
effective in suppressing the IL-1β-induced human carti-
lage matrix proteoglycan release in vitro [1]. In this report
we have addressed the in vivo efficacy of pomegranate con-
stituents and/or their metabolites that become bioavaila-
ble after oral ingestion PFE. It is also important to point
out that the polyphenolic content of the PFE powder (34
mg/Kg) employed in this study was equivalent to the
polyphenolic content of 175 ml of pomegranate juice
indicating that this is feasible in terms of human nutri-
tion. Inhibition of COX activity by constituents and/or
metabolites that became bioavailable via systemic circula-
tion provide the first direct evidence of pomegranate
extract-derived active principles in the plasma that signif-
icantly inhibited the COX-2 activity (P < 0.05). After the
oral ingestion of a single dose of PFE the inhibition of
COX-1 and COX-2 induced by rabbit plasma samples
indicated a COX-2/COX-1 ratio of 0.8 which is suggestive
of selective inhibition of COX-2 [38]. Selective COX-2
inhibition with COX-2/COX-1 ratios below 1 was previ-
ously reported for resveratrol and its analogues [56] but
selective inhibition of COX-2 by bioavailable constituents
or metabolites of a fruit or plant extract has not been
shown. In another study, bioavailability and COX inhibi-
tory activity of Pycnogenol constituents or their metabo-
lites in human serum was studied, but in this study the
effect was not found to be COX-2 selective as the COX-2/
COX-1 activity ratio was greater than 1 [34]. In a chronic
gastric ulcer model, consumption of sangre de grado
extract selectively suppressed the COX-2 mRNA expres-
sion in the ulcer bed but the effect on COX activity was
not studied [57]. Although COX-1 is constitutively
expressed while COX-2 is induced in an inflammatory
response, use of plant extracts or isolated polyphenols
directly in in vitro assays to inhibit COX activity fails to
address the question whether sufficiently high concentra-
tions of these flavonoids could be achieved in vivo to exert
the same effect [34]. Our results address this question and
also provide support to the reported use of pomegranate
extract for the treatment of inflammatory bowel diseases
or gastric ulcers by the practitioners of Ayurveda and
Unani systems of medicine [58].
Results of the present study also highlight the effective-
ness of bioavailable pomegranate fruit constituents and/
or metabolites present in the blood plasma to inhibit the
IL-1β-induced NO production in articular cartilage
chondrocytes. Biological activities of polyphenols present
in popular medicinal plants and herbs have been studied
extensively including inhibition of inflammatory stimuli-
induced responses in different cell and tissue types
[reviewed in [14]]. NO plays a pivotal role as second mes-
senger and an effecter molecule in a variety of tissues. NO
also have been defined as an important molecule in
inflammation and to the pathogenesis of osteoarthritis
(OA) as excessive production of NO induced by inflam-
matory cytokines in chondrocytes and other cell types in
arthritic joints has been related to the induction of apop-
tosis in chondrocytes [59]. Therefore, compounds that
inhibit excessive NO production may have beneficial ther-
apeutic effects in arthritis by blocking cartilage degrada-
tion. However, this needs to be evaluated first in an
animal model followed by controlled clinical trials.
Conclusion
These studies provide evidence to show that bioavailable
constituents and/or metabolites of PFE exert an anti-
inflammatory effect by inhibiting the activity of eicosa-
noid generating enzymes and the production of NO. This
further suggests that consumption of PFE may be of value
in inhibiting inflammatory stimuli-induced cartilage
breakdown and production of inflammatory mediators in
arthritis.
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